October 5, 2011 -- SciClone Pharma announced a share repurchase program of up to $20 million over the next 24 months. SciClone, headquartered in California, commercializes and markets Western drugs in China. In addition to boosting the company’s stock price, the repurchase program will partially offset the 8.3 million shares that may be offered by the previous owners of NovaMed, which SciClone acquired in April of this year. Despite its solid financial performance, SciClone’s stock price remains low. More details....
Stock Symbol: (NSDQ: SCLN)
